Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013438 | 0.92 | MAPT (0.37) | MAPTKDM4EAVPR1ASCN9ASCN10A | |
| SCHEMBL23577289 | 0.92 | MAPT (0.37) | MAPTKDM4EAVPR1ASCN9ASCN10A | |
| SCHEMBL30047562 | 0.91 | MAPT (0.37) | MAPTKDM4EAVPR1ASCN9ASCN10A | |
| SCHEMBL29138455 | 0.91 | MAPT (0.37) | MAPTKDM4EAVPR1ASCN9ASCN10A | |
| SCHEMBL23601254 | 0.91 | KDM4E (0.37) | MAPTKDM4ERXRARXRBRXRG | |
| SCHEMBL23601036 | 0.90 | MAPT (0.35) | MAPTKDM4ERXRARXRBRXRG | |
| SCHEMBL23601544 | 0.89 | MAPT (0.37) | MAPTKDM4ESCN9ASCN10AACHE | |
| SCHEMBL23601079 | 0.89 | KDM4E (0.34) | MAPTKDM4ERXRARXRBRXRG | |
| SCHEMBL24814766 | 0.88 | MAPT (0.39) | MAPTKDM4EAVPR1A | |
| SCHEMBL30048203 | 0.88 | MAPT (0.39) | MAPTKDM4EAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885KDM4E 1748/4885RXRA 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.